Browsing Over 32 Presentations

Sort By
Preclinical evidence of efficacy (ID 5) Educational session

Comparison of preclinical data across CDK 4-6 (ID 15)

Lecture Time
17:40 - 18:00
Speakers
  • Romano Danesi (Pisa, IT)
Session Name
Preclinical evidence of efficacy (ID 5)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
The concept of CDK inhibition according to the targeted CDK subtype (ID 4) Educational session

DNA damage and checkpoint kinases (ID 10)

Lecture Time
15:30 - 15:50
Speakers
  • Fabrizio D'Adda di Fagagna (Milan, IT)
Session Name
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
The role of CDK along the mitotic process in normal and pathological condition (ID 3) Educational session

The biology of the CDK4–CDK6–RB pathway (ID 5)

Lecture Time
13:40 - 14:00
Speakers
  • Tobias Otto (Aachen, DE)
Session Name
The role of CDK along the mitotic process in normal and pathological condition (ID 3)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
13:20 - 14:30
The concept of CDK inhibition according to the targeted CDK subtype (ID 4) Educational session

Mechanism of resistance to CDKs inhibitors (ID 33)

Lecture Time
15:50 - 16:10
Speakers
  • Giulio Draetta (Houston, US)
Session Name
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
CDK4 and CDK6 inhibitors in breast cancer (ID 8) Educational session

Palbociclib (ID 28)

Lecture Time
13:30 - 13:50
Speakers
  • Javier Cortes (Madrid, ES)
Session Name
CDK4 and CDK6 inhibitors in breast cancer (ID 8)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
Interaction between CDKs, CDKI and other targets (ID 6) Educational session

Q&A (ID 22)

Lecture Time
10:40 - 10:50
Session Name
Interaction between CDKs, CDKI and other targets (ID 6)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
Interaction between CDKs, CDKI and other targets (ID 6) Educational session

Synthetic lethality (ID 17)

Lecture Time
09:00 - 09:20
Speakers
  • Rene Bernards (Amsterdam, NL)
Session Name
Interaction between CDKs, CDKI and other targets (ID 6)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
Preclinical evidence of efficacy (ID 5) Educational session

Preclinical evidence of activity of palbociclib (ID 12)

Lecture Time
16:40 - 17:00
Speakers
  • Angel Guerrero (Valencia, ES)
Session Name
Preclinical evidence of efficacy (ID 5)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
The concept of CDK inhibition according to the targeted CDK subtype (ID 4) Educational session

CDK2 as the bypass kinase for CDK4/6 inhibition (ID 7)

Lecture Time
14:50 - 15:10
Speakers
  • Nicholas Turner (London, GB)
Session Name
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
Role of CDK 4-6 inhibitors across solid tumors (ID 9) Panel Discussion

Panel Discussion (ID 35)

Lecture Time
15:20 - 16:05
Speakers
  • Alberto Bardelli (Candiolo, IT)
  • Josep Tabernero (Barcelona, ES)
Session Name
Role of CDK 4-6 inhibitors across solid tumors (ID 9)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
15:20 - 16:05
CDK4 and CDK6 inhibitors in breast cancer (ID 8) Educational session

Abemaciclib (ID 30)

Lecture Time
14:10 - 14:30
Speakers
  • Antonio Llombart-Cussac (Valencia, ES)
Session Name
CDK4 and CDK6 inhibitors in breast cancer (ID 8)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
The disappointing results of initial CDKI and their role in other disease (ID 7) Educational session

Dinaciclib (ID 24)

Lecture Time
11:10 - 11:35
Speakers
  • Cristina Saura (Barcelona, ES)
Session Name
The disappointing results of initial CDKI and their role in other disease (ID 7)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
11:10 - 12:40